RNA-seq Analysis of PBMC in Patients With OPLL

Characteristics of Transcriptome Expression Profile of PBMCs in Patients With Ossification of the Posterior Longitudinal Ligament

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04963101

Enrollment

Registered

2021-07-15

Start date

2021-06-25

Completion date

2022-06-30

Last updated

2021-07-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bioinformatics, OPLL, PBMCs, Transcriptome

Brief summary

In this study, we planned to identify transcriptome expression profiles (circRNAs, lncRNAs, and mRNAs) from peripheral blood mononuclear cells (PBMCs) of 30 patients with OPLL and 30 other non-OPLL patients by high-throughput sequencing.Sequence analysis was used to predict miRNAs that might bind circRNAs and lncRNAs.Through bioinformatics analysis, competitive endogenous RNAs (cerRNAs), as well as coexpression networks among circRNAs, lncRNAs, miRNAs, and mRNAs, were constructed to provide key molecules and signaling pathways associated with OPLL.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Inclusion criteria

1. Voluntarily participate in the clinical study and sign the informed consent; 2. All OPLL patients meet the diagnostic criteria set out in the JOA Clinical Practice Guidelines for Spinal Ligament Osification 2019; 3. Age ≥18, gender unlimited; 4. All non-OPLL patients and healthy volunteers have no serious diseases of the heart, lung, brain, liver, kidney and blood system, such as autoimmune diseases, tumors, psychosis, infectious diseases, etc., and have no bad habits or recent history of taking special drugs.

Exclusion criteria

1. Unable to sign the informed consent; 2. Patients who do not meet the inclusion criteria or diagnostic criteria; 3. \<18 years old; 4. Women planning to become pregnant/lactating/pregnant; 5. Complicated with serious heart, lung, brain, liver, kidney, blood system diseases, such as autoimmune diseases, tumors, mental illness, infectious diseases, drug addiction and other bad addicts;Those who have recently taken special drugs; 6. Individuals who do not agree to donate peripheral blood or who are obviously uncomfortable with drawing blood.

Design outcomes

Primary

Measure	Time frame
circRNA, lncRNA, mRNA	1 year

Countries

China

Contacts

Primary ContactNing Jiang, M.D

jiangn57@mail2.sysu.edu.cn+86 15653868023

Outcome results